Premium
Evaluation of clinical efficacy of Polycan for bone metabolism in Korean women: A randomized, double‐blind, placebo‐controlled clinical study
Author(s) -
Park SooHyun,
Kim SunYoung,
Back HyangIm,
Jeon JiYoung,
Kim MinGul,
Chae SooWan,
Kim DalSik
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.lb349
Subject(s) - deoxypyridinoline , bone remodeling , placebo , medicine , bone resorption , osteoporosis , adverse effect , endocrinology , resorption , randomized controlled trial , osteocalcin , gastroenterology , physiology , pathology , chemistry , biochemistry , alkaline phosphatase , alternative medicine , enzyme
Osteoporosis is a metabolic bone disease that results from a disturbance in normal bone remodeling, titling the balance to bone resorption over formation. Polycan known as a suppressor of bone resorption and enhancer of bone formation in animal experiment. To investigate the effect of Polycan on bone metabolism, we carried out 12 weeks, randomized, double‐blind, placebo‐controlled clinical trial for Korean woman. Sixty subjects were randomly assigned to two treatment groups with daily doses of Polycan (n=30, 150 mg), placebo group (n=30, 150 mg). Outcomes included measures of efficacy (deoxypyridinoline [DPYR], osteocalcin [OSC]) and safety (adverse events, laboratory test, anthropometric, electrocardiogram, and vital sign). 58 subjects (29 Polycan group, 29 placebo group) finished the study. After the 12 weeks of supplementation, DPYR is significantly decreased and OSC is significantly increased in both groups. There was no significant difference between Polycan and placebo group but OSC showed a tendency to increase in Polycan group. In conclusion polycan has positive effect on bone metabolism. And there was no adverse events in both groups.